Lung cancer is the most lethal cancer, killing ~1.3 million people worldwide every year. Early diagnosis could increase its survival by 3-4 folds. Expected survival is greater than 70% if the cancer is discovered in early stage. The recent NLST trial has shown that annual CT scans for risk cohort can reduce the lung cancer related mortality by 20%. Therefore the yield of screening for lung cancer is not a question anymore and the urgent unmet need is to define the group that is under a high risk for lung cancer. Our lab is focusing on revealing non-invasive biomarkers as for early detection of lung cancer.